Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in corticotrophs | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 127 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8013
Sealed predictions
- RAB3B in dopamine neurons, braak+0.42 (p 0.262) → -0.55 (p 0.125)receipt 8020
In the sealed studies
- The synaptic vesicle cycle in resilient donors: did not hold
Swarm cases
receipt 8020: RAB3B in dopamine neurons, braak
- power
- full sample -0.15 (p 0.549, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.549, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.509, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.04, sign flips 0; without severely affected donors -0.15 (p 0.549, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAB3B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts